Alzheimer’s disease

Halting the disease progression would lead to great benefits to patients, families and caregivers.

Read more

Parkinson’s disease

The medical need of treatments is high due to the lack of drugs affecting the underlying pathology.

Read more

Complete Spinal Cord Injury

We are developing an innovative treatment that aims to improve the patients’ quality of life.

Read more

Press releases

• May 20, 2019 - Regulatory press releaseBioArctic receives MEUR 15 milestone payment from Eisai for start of BAN2401 confirmatory Phase 3 study in early Alzheimer’s Disease
• May 10, 2019 - Other press releaseBioArctic: Alzheimer’s Clinical Trials Consortium and Eisai announce BAN2401 to be evaluated in clinical study for prevention of Alzheimer’s disease
• May 9, 2019 - Other press releaseBioArctic’s Board of Directors and management increase their shareholdings

Archive

Interim Report Q1 2019

BioArctic AB published the Interim Report for the period January – March 2019, May 9, 2019.

• Report
• Presentation
• Webcast

Read the report

Calendar

• June 4, 2019 - June 6, 2019Jefferies 2019 Global Healthcare Conference, New York
• June 10, 2019Redeye Growth Day, Stockholm, Sweden
• July 11, 2019Interim Report January – June 2019

All events